ARTICLE | Clinical News
Benjorna: Phase III data
July 11, 2016 7:00 AM UTC
The double-blind, U.S. Phase III HLD-200-108 trial in 161 patients ages 6-12 with ADHD in a naturalistic setting showed that once-daily oral HLD-200 met the primary endpoint of improving ADHD-RS-IV to...